Literature DB >> 871217

Pharmacokinetic observations of phenytoin disposition in the newborn and young infant.

P M Loughnan, A Greenwald, W W Purton, J V Aranda, G Watters, A H Neims.   

Abstract

The pharmacokinetic profile of phenytoin (DPH) was studied in 30 infants aged 2 days to 96 weeks. The plasma DPH half-life during the first week of life in term infants was prolonged and very variable (20-7 +/- 11-6 h, mean +/-SD). Thereafter the plasma half-life was much shorter (7-6 +/- 3-5 h). In preterm infants the half-life was much longer (75-4 +/- 64-5 h) and more variable. The mean apparent volume of distribution was similar in these groups of infants: preterm newborn 0-80 +/- 0-22 l/kg, term infants during the first week of life 0-80 +/- 0-26 l/kg, and term infants greater than 2 weeks of age 0-73 +/- 0-18 l/kg. Predictions of steady-state plasma DPH concentrations, based on these kinetic parameters, were confirmed. Very low "trough" plasma DPH concentrations were observed after the 14th postnatal day in 19 infants receiving 8 mg/kg per 24 h orally. On the other hand, infants of less than one week of age receiving the same dose, especially if preterm, frequently showed drug accumulation to toxic plasma DPH concentrations. The impaired binding of DPH to newborn plasma protein was confirmed but "normal adult values" were approached by the age of 3 months. An intravenous loading dose of 8 mg/kg (sodium phenytoin) can be expected to generate a mean plasma DPH concentration of 10 mg/l (40 micronmol/l) in the newborn. Loading doses of up to 12 mg/kg were given without untoward effects. During the first week or so of life plasma Dph half-life is so variable that no fixed dosage regimen can be derived from the available data. Beyond the second week of life, however, a dose of 8 mg/kg per 24 h is probably inadequate for most infants.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 871217      PMCID: PMC1544674          DOI: 10.1136/adc.52.4.302

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  27 in total

Review 1.  Drug metabolism in the human neonate.

Authors:  M G Horning; C M Butler; J Howlin; R M Hill
Journal:  Life Sci       Date:  1975-03-01       Impact factor: 5.037

2.  DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN.

Authors:  O SVENSMARK; F BUCHTHAL
Journal:  Am J Dis Child       Date:  1964-07

3.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

4.  Urinary corticosteriod and diphenylhydantoin metabolite patterns in neonates exposed to anticonvulsant drugs in utero.

Authors:  J W Reynolds; B L Mirkin
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

5.  Plasma concentrations of phenobarbital in the neonate during prophylaxis for neonatal hyperbilirubinemia.

Authors:  A Wallin; B Jalling; L O Boréus
Journal:  J Pediatr       Date:  1974-09       Impact factor: 4.406

6.  Anticonvulsant drugs in human epileptogenic brain. Correlation of phenobarbital and diphenylhydantoin levels with plasma.

Authors:  A L Sherwin; A A Wisen; C D Sokolowski
Journal:  Arch Neurol       Date:  1973-08

7.  Urinary excretion of diphenylhydantoin metabolites in newborn infants.

Authors:  A Rane
Journal:  J Pediatr       Date:  1974-10       Impact factor: 4.406

8.  Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.

Authors:  H E Booker; B Darcey
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

9.  Diazepam elimination in premature and full term infants, and children.

Authors:  P L Morselli; N Principi; G Tognoni; E Reali; G Belvedere; S M Standen; F Sereni
Journal:  J Perinat Med       Date:  1973       Impact factor: 1.901

10.  Studies on glucoronide formation in newborn infants and older children. Measurement of paminophenol glucuronide levels in the serum after an oral dose of acetanilid.

Authors:  M F VEST; R R STREIFF
Journal:  AMA J Dis Child       Date:  1959-12
View more
  18 in total

Review 1.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

Review 2.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.

Authors:  Khaled Abduljalil; Masoud Jamei; Amin Rostami-Hodjegan; Trevor N Johnson
Journal:  AAPS J       Date:  2014-04-04       Impact factor: 4.009

Review 4.  Clinical pharmacology of the perinatal period and early infancy.

Authors:  P L Morselli
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 5.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

6.  Maturation of caffeine elimination in infancy.

Authors:  J V Aranda; J M Collinge; R Zinman; G Watters
Journal:  Arch Dis Child       Date:  1979-12       Impact factor: 3.791

Review 7.  Plasma protein binding of drugs in pregnancy.

Authors:  E Perucca; A Crema
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 8.  Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics.

Authors:  H Nau; W Kuhnz; H J Egger; D Rating; H Helge
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Pharmacological treatment of neonatal seizures: a systematic review.

Authors:  Laurel A Slaughter; Anup D Patel; Jonathan L Slaughter
Journal:  J Child Neurol       Date:  2013-01-14       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.